Nervous system: Ependymomas

Identity

Note	Ependymomal neoplasms are tumors of children and young adults, originating from the cerebral ventricle or from the spinal canal. In the central nervous system (CNS), they account for 3 ‚ 9 % of all neuro-epithelial tumors .

Classification

Note	Histological feature of ependymoma : perivascular rosettes - Anne Marie Capodano
	Ependymomas are well-delineated moderately cellular gliomas. Histolological features are perivascular pseudo rosettes and ependymal rosettes WHO classification differentiate four major types : 1. Ependymoma and variants (grade II) : - Cellular ependymoma : a variant of ependymoma with conspicuous cellularity but often less prominent pseudo-rosette or rosette formation. - Papillary ependymoma : a rare variant which looks like choroid plexus papilloma. - Clear cell ependymoma : a rare variant which may be confused with oligodendroglioma neurocytoma or metastatic renal cell carcinoma. 2. Anaplastic (malignant) ependymoma (grade III) : An ependymoma with histological evidence of anaplasia. 3. Myxopapillary ependymoma (grade I) : It occurs almost exclusively in the conus-cauda-filum terminale region, with a generally favourable prognosis. 4. Subependymoma (grade I) : Benign tumor composed of nests of ependymomal cells in a dense glial fibrillary matrix

Clinics and Pathology

Epidemiology	In children, 30 % of ependymomas appear before the age of 3 years and are more aggressive than in adults. Nearly 90 % of pediatric ependymomas are intra cranial : they occur in supratentorial or posterior fossa locations, and only 10 % are intraspinal. Ependymomas account for 6 to 12 % of brain tumors in children and represent the third most common central nervous system neoplasms in this age range, following astrocytoma and medulloblastoma. In adults, 60 % of ependymomas are tumors of spinal cord and only 40 % are intracranial. Intramedullary spinal ependymomas can be seen in patients with neurofibromatosis type 2 (NF2), a hereditary disease. Clustering of ependymomas has been noted in some families suggesting inheritance of a genetic susceptibility to this type of tumor.
Clinics	Clinical manifestations of these tumors are localization dependent.
Pathology	Immunochemistry: The great majority of ependymomas display GFAP immunoreactivity. It is usually observed in pseudo-rosettes, but GFAP is not specific of ependymomas. It is observed in all gliomas. Ependymomas typically express S 100 protein and Vimentin. In ependymomas WHO grade II, epithelial membrane antigen (EMA) immunoreactivity has been reported.
Treatment	The treatment of ependymomas is mainly exeresis of tumor and radiotherapy after exeresis
Prognosis	Ependymoma is a recurrent tumor. The identification of parameters with prognostic value in ependymomas is very important, but controverted. By order of importance the following factors are considered : Age and extent of resection Prognosis in children is significantly worse than in adults. The childrenžs cancer group reported a 5 year progression-free survival of 5 % in children with intracranial ependymomas. A retrospective analysis of 83 pediatric ependymomas revealed are below 3 years incomplete tumour resection as indication of a poor outcome. In adult patients survival at 10 years is 45 %. Complete or near complete resection emerged as an independent prognostic factor. Localization Supratentorial ependymomas are associated with better survival rates compared to posterior fossa tumors. Spinal ependymomas are associated with better outcome than cerebral tumors. Cerebrospinal localization shows a poor prognosis.

Cytogenetics

Cytogenetics Morphological	No specific cytogenetic abnormality has been described. But ependymomas with 30 % incidence of aberrations involve chromosome 22 as the most frequent change. Monosomy 22 as well as deletions or translocations involving 22q can appear Less frequent are structural abnormalities of chromosomes 1, 6, and 17 and numerical abnormalities of 7, 9, 12 and 20. Monosomy 10 was reported in few cases of anaplastic ependymomas associated with LOH of 17p. Monosomy 13 was observed in eight cases half of which occurred in paediatrics patients. Rearrangements or deletions of chromosome 6 were reported in five tumors.
	Partial karyotype of a cell of ependymoma : 46, XX, del(22)(q11) with R-banding - Anne Marie Capodano

Genes involved and Proteins

Note

Genes involved in ependymomas remain to be uncovered. Mutations or deletions of the tumor suppressor genes CDKN2 A et CDKN2 B and amplification of CDK4 or CCND1 have been reported. Mutations of TP53 were occasionally observed in ependymomas. Increased incidence of ependymomas in neurofibromatosis type 2 has suggest that NF2 represents an obvious candidate gene. Some authors have presented evidence for mutations of NF2 suppressor gene at 22 q12 . Whereas others have been unable to identify such mutations of the NF2. Investigators show that the most frequently recurrent genomic loss in ependymomas does not involve the proximal 22 q11.2 chromosome region. They suggest that another not-yet identified tumor suppressor gene located distally to the HSNF5 / INT1 locus on the 22q and independent of NF2 locus may be involved in ependymomas.

External links

Orphanet	Ependymoma
Other database	Ependymoma (St. Jude Children's Research Hospital, USA)
Other database	Ependymoma (UCLA Division of Neurosurgery, USA)

Bibliography

An immunocytochemical comparison of the glia-associated proteins glial fibrillary acidic protein (GFAP) and S-100 protein (S100P) in human brain tumors.

Kimura T, Budka H, Soler-Federsppiel S.

Clin.Neuropathol. 1986;5(1):21-27.

PMID 3512139

Cytogenetic abnormalities in human ependymomas.

Stratton MR, Darling J, Lantos PL, Cooper CS, Reeves BR.

Int.J.Cancer 1989;44(4):579-81.

PMID 2793229

Cancer in the families of children with soft tissue sarcoma.

Birch JM, Hartley AL, Blair V, Kelsey AM, Harris M, Teare MD et al.

Cancer 1990;66(10):2239-2248.

PMID 2224780

The new WHO classification of brain tumours.

Kleihues P, Burger PC, Scheithauer BW.

Brain Pathol. 1993;3(3):255-268.

PMID 8293185

Adult intramedullary spinal cord ependymomas: the result of surgery in 38 patients.

Epstein FJ, Farmer JP, Freed D.

J.Neurosurg. 1993;79(2):204-209.

Chromosomes in the genesis and progression of ependymomas.

Rogatto SR, Casartelli C, Rainho CA, Barbieri-Neto J.

Cancer Genet Cytogenet 1993;69(2):146-152.

PMID 8402555

The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC.

Rubio MP, Correa KM, Ueki K, Mohrenweiser HW, Gusella JF, von Deimling A et al.

Cancer Res. 1994;54(17):4760-4763.

PMID 8062276

Intracranial ependymomas of childhood: long-term outcome and prognostic factors.

Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL et al.

Neurosurgery 1995;37(4):655-666.

PMID 8559293

Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

Ernestus RI, Schroder R, Stutzer H, Klug N.

Childs Nerv.Syst. 1996;12(9):522-526.

PMID 8906366

Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors.

Sato K, Schauble B, Kleihues P, Ohgaki H.

Int.J.Cancer 1996;66(3):305-308.

PMID 8621248

The molecular biology of ependymomas.

Hamilton RL, Pollack IF.

Brain Pathol. 1997;7(2):807-822.

PMID 9161731

Multiple ependymomas in a patient with Turcot's syndrome.

Torres CF, Korones DN, Pilcher W.

Med.Pediatr.Oncol. 1997;28(1):59-61.

PMID 8950338

Molecular cytogenetic studies of pediatric ependymomas.

Kramer DL, Parmiter AH, Rorke LB, Sutton LN, Biegel JA.

J.Neurooncol. 1998;37(1):25-33.

PMID 9525835

Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's

Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer JR et al.

Cancer Group. J.Neurosurg. 1998;88(4):695-703.

PMID 9525716

A. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location.

Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo

Pediatr.Neurosurg. 1998;28(3):135-142.

PMID 9705591

A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors.

Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J et al.

J.Pediatr.Hematol.Oncol. 1999;21(3):203-211.

PMID 10363853

Cytogenetic study of 33 ependymomas.

Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, Figarella-Branger D, Lena G, Dufour H et al.

Cancer Genet Cytogenet 1999;115(2):96-99.

PMID 10598140

Fluorescence in situ hybridization determination of 22q12-q13 deletion in two intracerebral ependymomas.

Rousseau-Merck M, Versteege I, Zattara-Cannoni H, Figarella D, Lena G, Aurias A, Vagner-Capodano AM.

Cancer Genet Cytogenet 2000;121(2):223-227.

PMID 11063814

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Contributor(s)

Written	04-2001	Anne Marie Capodano

Citation

This paper should be referenced as such :

Capodano AM . Nervous system: Ependymomas. Atlas Genet Cytogenet Oncol Haematol. April 2001 . URL : http://AtlasGeneticsOncology.org/Tumors/EpendymomID5016.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Thu Apr 17 14:14:31 2008

For comments and suggestions or contributions, please contact us